Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Asif Choudhary

Child & Adolescent Psychiatry Sedalia, MO Medical Doctor

NPI 1134560865 CMS profile 1107593

1795 W Main St, Sedalia, MO 65301

Open in the dashboard

General payments

$756

39 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asif Choudhary of Sedalia, MO is reported in the CMS Open Payments database as having received $756 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $258 14
2024 General $190 10
2023 General $273 13
2022 General $20 1
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asif Choudhary
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Asif Choudhary were reported at $258. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Asif Choudhary Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $15 $115 $31–$326 $132
2022 $20 $124 $40–$382 $149
2023 $273 $130 $45–$420 $160
2024 $190 $141 $42–$490 $164
2025 $258 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $331 17 payments
  2. Corium, Inc. $257 11 payments
  3. Ironshore Pharmaceuticals Inc. $73 5 payments
  4. Collegium Pharmaceutical, Inc. $34 2 payments
  5. Tempus AI, Inc $17 1 payment
  6. Almatica Pharma LLC $15 1 payment
  7. AbbVie, Inc. $15 1 payment
  8. Vertical Pharmaceuticals, LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $756 39 payments
Products named General payments · program years 2021–2025
  1. Azstarys $257 11 payments
  2. Qelbree Viloxazine Hydrochloride $222 12 payments
  3. QELBREE Psychology $108 5 payments
  4. JORNAY PM Central Nervous System Stimulant $73 5 payments
  5. Jornay PM Adhd $34 2 payments
  6. LOREEV XR $15 1 payment
  7. VRAYLAR $15 1 payment
  8. Relexxii $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

340

Median for Psychiatry: 574

Drug cost

$13,603

Median for Psychiatry: $27,624

Branded share of claims

25.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 12 $5,713
Paliperidone Er Paliperidone Brand 20 $2,245
Aripiprazole Generic 22 $2,084
Bupropion Xl Bupropion Hcl Brand 30 $871
Hydroxyzine Hcl Generic 29 $683
Buspirone Hcl Generic 29 $429
Duloxetine Hcl Generic 36 $348
Citalopram Hbr Citalopram Hydrobromide Brand 25 $291
Clonazepam Generic 31 $229
Trazodone Hcl Generic 31 $217

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $106
$106 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $53
$53 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record